Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti‐β7 integrin therapy for inflammatory bowel disease

BACKGROUND: Novel treatments with superior benefit‐risk profiles are needed to improve the long‐term prognosis of patients with inflammatory bowel disease (IBD). Etrolizumab—a monoclonal antibody that specifically targets β7 integrins—is currently under phase III clinical evaluation in IBD. AIM: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, M. T., Keir, M. E., Erickson, R., Stefanich, E. G., Fuh, F. K., Ramirez‐Montagut, T., McBride, J. M., Danilenko, D. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001693/
https://www.ncbi.nlm.nih.gov/pubmed/29601644
http://dx.doi.org/10.1111/apt.14631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001693/
https://www.ncbi.nlm.nih.gov/pubmed/29601644
http://dx.doi.org/10.1111/apt.14631

Ejemplares similares